Advanced search
Publication Cover
Nutrition and Cancer Volume 71, 2019 - Issue 5
Submit an article Journal homepage
160
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status

Takayuki FujioDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan; ;Department of Hematology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan
,
Kazuhisa NakashimaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
,
Tateaki NaitoDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-4047-2929
ORCID Icon,
Haruki KobayashiDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
,
Shota OmoriDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
,
Kazushige WakudaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
,
Akira OnoDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
,
Hirotsugu KenmotsuDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
,
Haruyasu MurakamiDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
&
Toshiaki TakahashiDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
show all
Pages 767-771 | Received 31 Jul 2018, Accepted 26 Nov 2018, Published online: 26 Jan 2019

References

  • NCCN Clinical Practice Guideline in Oncology. Non-Small Cell Lung Cancer. Version 7. 2015. http://www.nccn.org.
  • Zukin M, Barrios CH, Rodrigues Pereira J, De Albuquerque Ribeiro R, de Mendonça Beato CA, et al.: Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. JCO 31, 2849–2853, 2013.
  • Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, et al.: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92, 2639–2647, 2001.
  • Minami S, Ogata Y, Ihara S, Yamamoto S, and Komuta K: Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma. Lung Cancer (Auckl) 7, 99–110, 2016.
  • Forrest LM, McMillan DC, McArdle CS, Angerson WJ, and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89, 1028–1030, 2003.
  • Forrest LM, McMillan DC, McArdle CS, Angerson WJ, and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90, 1704–1706, 2004.
  • Crumley AB, Stuart RC, McKernan M, McDonald AC, and McMillan DC: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol 23, e325–e329, 2008.
  • Espinosa E, Feliu J, Zamora P, González Barón M, Sánchez JJ, et al.: Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12, 67–76, 1995.
  • Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, et al.: The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer 77, 383–388, 2012.
  • Jiang AG and Lu HY: The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy. J Chemother 27, 35–39, 2015.
  • Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, et al.: Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 23, 1699–1708, 2015.
  • Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69, 491–497, 1980.
  • Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375, 1823–1833, 2016.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.